Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target cells at ...
Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...
The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...
Oxford University is hoping to create a vaccine to stop the disease 20 years before it develops, as part of a joint project ...
GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.
Scientists at Oxford University and drugmaker GSK to ‘detect the undetectable’ and identify changes in cells that start up to ...
GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...
A new cancer vaccine is being developed which scientists hope could target the disease before it takes hold. The University ...
(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback